Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

• Status: RECRUITING
• Trial end date: 2034-12-31

Summary

Researchers are looking for new ways to treat triple-negative breast cancer (TNBC) and hormone receptor (HR) low positive/human epidermal growth factor receptor-2 (HER2) negative breast cancer. The main goals of this study are to learn:

• About the safety of the study treatments and if people tolerate them
• If people who receive patritumab deruxtecan, pembrolizumab, and chemotherapy before surgery have fewer cancer cells removed during surgery compared to those who receive only pembrolizumab (pembro) and chemotherapy.

• Phase: PHASE2

Details

• Lead Sponsor: Merck Sharp & Dohme LLC
• Collaborator: Daiichi Sankyo
• Treatments: Capecitabine; Carboplatin; Cyclophosphamide; Doxorubicin; Epirubicin; olaparib; Paclitaxel; patritumab deruxtecan; pembrolizumab